GlassScriptPhysician profile
Victor A Shada
NPI 1851390728
$14,533.72
in general payments reported to CMS, 2019-2025
57 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $1,783 · 2021: $2,071 · 2022: $2,000 · 2023: $2,361 · 2024: $2,224 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,800.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,080.19 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $2,066.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $894.68 | 2019-2025 | Farxiga, Airsupra, Brilinta |
| Takeda Pharmaceuticals U.S.A., INC. | $881.39 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $871.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $820.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $732.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $686.45 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $629.79 | 2019-2024 | Verquvo, Belsomra, Vaxneuvance |
| Amgen INC. | $518.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $398.90 | 2019-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.95 | 2023-2025 | Caplyta |
| Allergan, INC. | $334.39 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $300.49 | 2023-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $226.67 | 2019-2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Shada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.